S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
The Collapse of 2022 Has Begun (Ad)pixel
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse back in January – reveals his strategy: (Ad)pixel
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse back in January – reveals his strategy: (Ad)pixel
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
Montana site fouled by copper smelter to get final cleanup
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
The Collapse of 2022 Has Begun (Ad)pixel
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse back in January – reveals his strategy: (Ad)pixel
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse back in January – reveals his strategy: (Ad)pixel
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
Montana site fouled by copper smelter to get final cleanup
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
The Collapse of 2022 Has Begun (Ad)pixel
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse back in January – reveals his strategy: (Ad)pixel
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse back in January – reveals his strategy: (Ad)pixel
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
Montana site fouled by copper smelter to get final cleanup
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
The Collapse of 2022 Has Begun (Ad)pixel
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse back in January – reveals his strategy: (Ad)pixel
MarketBeat: Week in Review 9/26 – 9/30
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse back in January – reveals his strategy: (Ad)pixel
Danish Energy Agency says Nord Stream 2 gas pipeline under Baltic Sea appears to have stopped leaking gas
Montana site fouled by copper smelter to get final cleanup
NASDAQ:SNOA

Sonoma Pharmaceuticals - SNOA Stock Forecast, Price & News

$2.13
0.00 (0.00%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.12
$2.18
50-Day Range
$2.10
$3.66
52-Week Range
$2.07
$7.20
Volume
5,717 shs
Average Volume
15,463 shs
Market Capitalization
$6.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
SNOA stock logo

About Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.

Receive SNOA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sonoma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SNOA Stock News Headlines

See More Headlines
Receive SNOA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sonoma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SNOA Company Calendar

Last Earnings
8/11/2022
Today
10/01/2022
Next Earnings (Estimated)
11/21/2022
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SNOA
Employees
14
Year Founded
1999

Profitability

Net Income
$-5,090,000.00
Pretax Margin
-40.55%

Debt

Sales & Book Value

Annual Sales
$12.63 million
Book Value
$2.81 per share

Miscellaneous

Free Float
2,810,000
Market Cap
$6.60 million
Optionable
Not Optionable
Beta
0.96

Social Links


Key Executives

  • Ms. Amy M. Trombly (Age 54)
    CEO, Pres & Director
    Comp: $428k
  • Mr. Jerome Dvonch (Age 53)
    Chief Financial Officer
    Comp: $221.91k
  • Mr. Bruce Thornton (Age 58)
    COO & Corp. Sec.
    Comp: $365k
  • Dr. Robert Northey (Age 65)
    Exec. VP of R&D
  • Ms. Victoria Covel
    Assistant Controller













SNOA Stock - Frequently Asked Questions

How have SNOA shares performed in 2022?

Sonoma Pharmaceuticals' stock was trading at $4.56 at the start of the year. Since then, SNOA stock has decreased by 53.3% and is now trading at $2.13.
View the best growth stocks for 2022 here
.

When is Sonoma Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our SNOA earnings forecast
.

How were Sonoma Pharmaceuticals' earnings last quarter?

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) announced its quarterly earnings data on Thursday, August, 11th. The company reported ($0.29) EPS for the quarter. The business had revenue of $3.98 million for the quarter. Sonoma Pharmaceuticals had a negative trailing twelve-month return on equity of 49.64% and a negative net margin of 37.71%.

What other stocks do shareholders of Sonoma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sonoma Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), VelocityShares Daily 2x VIX Short-Term ETN (TVIX), Sorrento Therapeutics (SRNE), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Amarin (AMRN), Pfizer (PFE), Nabriva Therapeutics (NBRV), Verastem (VSTM) and Vaxart (VXRT).

What is Sonoma Pharmaceuticals' stock symbol?

Sonoma Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNOA."

How do I buy shares of Sonoma Pharmaceuticals?

Shares of SNOA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sonoma Pharmaceuticals' stock price today?

One share of SNOA stock can currently be purchased for approximately $2.13.

How much money does Sonoma Pharmaceuticals make?

Sonoma Pharmaceuticals (NASDAQ:SNOA) has a market capitalization of $6.60 million and generates $12.63 million in revenue each year. The company earns $-5,090,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis.

How can I contact Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals' mailing address is 645 MOLLY LANE SUITE 150, WOODSTOCK GA, 30189. The official website for the company is www.sonomapharma.com. The company can be reached via phone at (800) 759-9305, via email at dmcfadden@sonomais.com, or via fax at 707-283-0551.

This page (NASDAQ:SNOA) was last updated on 10/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.